OPKO Health Q2 loss narrows on higher IP revenue, lower costs

Overview

• US biopharma and diagnostics firm's Q2 revenue rose yr/yr, driven by higher IP and partnership revenue

• Q2 net loss narrowed to $8.4 mln from $148.4 mln a year earlier

• Company repurchased $13.2 mln of stock in Q2; $94.7 mln remains authorized

Outlook

• OPKO Health expects Q3 total revenue between $131 mln and $142 mln

• Company sees full-year 2026 total revenue between $560 mln and $585 mln

• OPKO Health projects full-year 2026 costs and expenses of $710 mln to $740 mln

Result Drivers

• IP AND PARTNERSHIP REVENUE - Higher Q2 revenue was mainly driven by increased revenue from transfer of intellectual property and partnerships, including shares received from amended Nicoya agreement and higher revenue from NGENLA, Eli Lilly, and Regeneron

• INTERNATIONAL PRODUCT SALES - Product revenue increased due to higher sales volumes in Spanish and Mexican operations and positive foreign exchange impact, partially offset by declines in other international markets

• SERVICE REVENUE DECLINE - Revenue from services fell due to the prior-year contribution from oncology assets sold to Labcorp in September 2025

Company press release: ID:nGNX8DJm1D

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities services peer group is "buy"

• Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 145.9% above its July 24 closing price of $1.22

Reuters Recommended Reads

• July 27 - FDA staff flags data concerns about Capricor's therapy; shares plunge

• July 27 - AstraZeneca drug prices evolving in response to Trump policy, executive says

• July 27 - Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)